{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:53:35Z","timestamp":1775714015424,"version":"3.50.1"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Colorectal cancer is a major healthcare burden, and modern management of non-metastatic disease largely depends on guideline-concordant care based on histopathologic staging and empiric systemic therapy. While multidisciplinary care pathways and standardized guidelines have improved outcomes at the population level, they fall short in addressing the inter-patient and intra-tumoral heterogeneity that contributes to treatment resistance, recurrence of the disease, and unnecessary toxicity. Using a hypothetical patient journey, this commentary highlights how current practice often fails to align with patient needs despite being guideline-concordant. We discuss the limitations of current treatment paradigms and the shortcomings of modern tools such as genomic profiling, highlighting the continued need for complementary approaches. We hypothesize that functional precision medicine approaches have the potential to complement existing treatment paradigms and improve therapeutic stratification. We provide illustrative examples of their potential utility drawn from our recent clinical correlation study on colorectal cancer, in which we reported an association between assay outcomes and clinical response in a retrospective cohort. Additionally, we demonstrate the ability to identify intra-patient heterogeneity in\n                    <jats:italic>ex vivo<\/jats:italic>\n                    drug responses, suggesting phenotypically distinct subpopulations with differential drug sensitivity. Further investigation leading to the integration of these or similar technologies alongside genomic and minimal residual disease assessments could refine therapy selection and improve existing surveillance strategies. Ultimately, we suggest that while guideline-concordant care remains necessary, it is not sufficient for all patients. Continued research efforts utilizing functional precision medicine technologies may enable colorectal cancer management to move toward a more personalized framework that maximizes patient outcomes.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1810895","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:21:25Z","timestamp":1775712085000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The patient journey and guideline-concordant care in colorectal cancer\u2014is current practice enough?"],"prefix":"10.3389","volume":"13","author":[{"given":"Carlton C.","family":"Barnett","sequence":"first","affiliation":[{"name":"Xilis, Inc.","place":["Durham, NC, United States"]},{"name":"University of Colorado School of Medicine","place":["Aurora, CO, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin R.","family":"Oliver","sequence":"additional","affiliation":[{"name":"Xilis, Inc.","place":["Durham, NC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Rutenberg","family":"Schoenberg","sequence":"additional","affiliation":[{"name":"Xilis, Inc.","place":["Durham, NC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans P.","family":"Smith","sequence":"additional","affiliation":[{"name":"Xilis, Inc.","place":["Durham, NC, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Roy","family":"Smythe","sequence":"additional","affiliation":[{"name":"Xilis, Inc.","place":["Durham, NC, United States"]},{"name":"University of Colorado School of Medicine","place":["Aurora, CO, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1200\/JCO.2015.63.0558","article-title":"Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database","volume":"34","author":"Shah","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1200\/JCO.2008.19.5362","article-title":"Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials","volume":"27","author":"Sargent","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3390\/cancers12020319","article-title":"Prognostic and predictive molecular biomarkers for colorectal cancer: updates and challenges","volume":"12","author":"Koncina","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrclinonc.2016.171","article-title":"From tumour heterogeneity to advances in precision treatment of colorectal cancer","volume":"14","author":"Punt","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"116114","DOI":"10.1016\/j.amjsurg.2024.116114","article-title":"NCCN guideline concordance in colon and rectal cancer patients within a comprehensive health system","volume":"240","author":"Robinson","year":"2025","journal-title":"Am J Surg"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/OP.23.00601","article-title":"Strategies to address the clinical practice gaps affecting the implementation of personalized medicine in cancer care","volume":"20","author":"Tsimberidou","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/ACM.0b013e3182806345","article-title":"Balancing personalized medicine and personalized care: academic medicine","volume":"88","author":"Cornetta","year":"2013","journal-title":"Acad Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.4103\/apjon.apjon_29_19","article-title":"Scope of practice, role legitimacy, and role potential for cancer care coordinators","volume":"6","author":"Panozzo","year":"2019","journal-title":"Asia Pac J Oncol Nurs"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/978-3-319-34244-3_15","article-title":"Pathologic features of primary colon, rectal, and anal malignancies","volume":"168","author":"Sundling","year":"2016","journal-title":"Cancer Treat Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.6004\/jnccn.2018.0021","article-title":"NCCN guidelines insights: colon cancer, version 2.2018","volume":"16","author":"Benson","year":"2018","journal-title":"J Natl Compr Cancer Netw"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1200\/jco.2025.43.16","article-title":"Cancer patients\u2019 messages about radiology\/pathology reports: insights for AI","volume":"43","author":"Chimonas","year":"2025","journal-title":"J Clin Oncol"},{"key":"ref16","year":"2009"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.6004\/jnccn.2020.7536","article-title":"Quality measurement in Cancer care: a review and endorsement of high-impact measures and concepts","volume":"18","author":"D\u2019Amico","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1023\/a:1008336415362","article-title":"Misunderstanding in cancer patients: why shoot the messenger?","volume":"10","author":"Gattellari","year":"1999","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/cpt.70091","article-title":"Patient perceptions of and experiences with risk evaluation and mitigation strategies","volume":"119","author":"Sarpatwari","year":"2026","journal-title":"Clin Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e00153623","DOI":"10.1590\/0102-311xen153623","article-title":"Consulting \u201cDr. Google\u201d: how the digital search for internet health information influences doctor-patient relationship","volume":"41","author":"de Arruda","year":"","journal-title":"Cad Saude Publica"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.psychres.2018.01.002","article-title":"Cyberchondria: overlap with health anxiety and unique relations with impairment, quality of life, and service utilization","volume":"261","author":"Mathes","year":"2018","journal-title":"Psychiatry Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"15119","DOI":"10.3748\/wjg.v20.i41.15119","article-title":"Evolution and future of laparoscopic colorectal surgery","volume":"20","author":"Kaiser","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00384-025-04930-w","article-title":"Advanced innovations in reducing anastomotic leak: a review of emerging biomaterial applications in colorectal surgery","volume":"40","author":"Chen","year":"2025","journal-title":"Int J Color Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/20476965.2018.1436909","article-title":"Multi-disciplinary planning in health care: a review","volume":"9","author":"Leeftink","year":"","journal-title":"Health Syst (Basingstoke)"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/bju.15495","article-title":"The cancer multidisciplinary team meeting: in need of change? History, challenges and future perspectives","volume":"128","author":"Winters","year":"2021","journal-title":"BJU Int"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.33546\/bnj.3343","article-title":"Concordance in the healthcare context: a concept analysis","volume":"10","author":"Taiwong","year":"2024","journal-title":"Belitung Nurs J"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/wjs.12391","article-title":"Association of commission on cancer accreditation with receipt of guideline-concordant care and survival among patients with colon cancer","volume":"49","author":"Chan","year":"2025","journal-title":"World J Surg"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"6461","DOI":"10.1245\/s10434-024-15875-9","article-title":"Accuracy of clinical staging of localized colon cancer: a National Cancer Database cohort analysis","volume":"31","author":"Emile","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1308\/rcsann.2017.0149","article-title":"Accelerated discharge within 72 hours of colorectal cancer resection using simple discharge criteria","volume":"100","author":"Emmanuel","year":"2018","journal-title":"Ann R Coll Surg Engl"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamasurg.2024.1555","article-title":"Time from colorectal cancer surgery to adjuvant chemotherapy: post hoc analysis of the SCOT randomized clinical trial","volume":"159","author":"G\u00f6genur","year":"2024","journal-title":"JAMA Surg"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1200\/jco.21.02538","article-title":"Adjuvant therapy for stage II colon cancer: ASCO guideline update","volume":"40","author":"Baxter","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12957-016-0826-4","article-title":"Prognostic factors in the patients with T2N0M0 colorectal cancer","volume":"14","author":"Xu","year":"2016","journal-title":"World J Surg Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"kae073","DOI":"10.1093\/jncics\/pkae073","article-title":"Measuring the quality of care in metastatic colorectal cancer: a scoping review of quality indicators","volume":"8","author":"Dunn","year":"2024","journal-title":"JNCI Cancer Spectr"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/jnci\/djy202","article-title":"Race, poverty, and initial implementation of precision medicine for lung Cancer","volume":"111","author":"Kehl","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1200\/JCO.23.00539","article-title":"Racial disparities in receipt of guideline-concordant care for early-onset colorectal cancer in the United States","volume":"42","author":"Nogueira","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref36","author":"Funk","year":"2016"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"29765","DOI":"10.1038\/srep29765","article-title":"Patterns of metastasis in colon and rectal cancer","volume":"6","author":"Riihim\u00e4ki","year":"2016","journal-title":"Sci Rep"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.dld.2023.11.041","article-title":"Colorectal cancer recurrence and its impact on survival after curative surgery: an analysis based on multistate models","volume":"56","author":"Balboa-Barreiro","year":"2024","journal-title":"Dig Liver Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1001\/jamaoncol.2023.5098","article-title":"Incidence of recurrence and time to recurrence in stage I to III colorectal Cancer: a Nationwide Danish cohort study","volume":"10","author":"Nors","year":"2024","journal-title":"JAMA Oncol"},{"key":"ref40","first-page":"101093","article-title":"Risk of recurrence in early-onset versus late-onset non-metastatic colorectal cancer, 2004\u20132019: a nationwide cohort study","volume-title":"Lancet Reg Health Eur","author":"Nors","year":"2024"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000540338","article-title":"Early-stage colon cancer surveillance: pattern and timing of recurrence and the role of 5-year surveillance","volume":"32","author":"Ferreira Pinto","year":"2024","journal-title":"GE Port J Gastroenterol"},{"key":"ref42","year":"2025"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1568009617666170209095143","article-title":"Metastatic colorectal cancer: role of target therapies and future perspectives","volume":"18","author":"Nappi","year":"2018","journal-title":"Curr Cancer Drug Targets"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.3390\/cells12121657","article-title":"Molecular mechanisms of colorectal liver metastases","volume":"12","author":"Tsilimigras","year":"2023","journal-title":"Cells"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"key":"ref46","author":"De Monaco","year":"2014"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s10147-014-0772-5","article-title":"Differences in attitude toward adjuvant chemotherapy between colorectal cancer survivors and the medical staff of Japanese hospitals","volume":"20","author":"Narita","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"ref48","first-page":"108805","article-title":"Age-related differences in patient preferences for adjuvant chemotherapy for high-risk endometrial cancer","volume-title":"Maturitas","author":"Wakkerman","year":"2026"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1634\/theoncologist.2010-0248","article-title":"Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility","volume":"16","author":"Park","year":"2011","journal-title":"Oncologist"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/01.cad.0000185185.64980.70","article-title":"Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer","volume":"17","author":"Choi","year":"2006","journal-title":"Anti-Cancer Drugs"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1007\/s00520-013-1905-5","article-title":"Oxaliplatin-induced peripheral neuropathy\u2019s effects on health-related quality of life of colorectal Cancer survivors","volume":"21","author":"Tofthagen","year":"2013","journal-title":"Support Care Cancer"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the percentage of US patients with Cancer who benefit from genome-driven oncology","volume":"4","author":"Marquart","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the expanding landscape of clinical actionability for patients with cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/s41416-022-01913-4","article-title":"Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing","volume":"127","author":"Jan","year":"2022","journal-title":"Br J Cancer"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"912641","DOI":"10.3389\/fmed.2022.912641","article-title":"Functional drug screening in the era of precision medicine","volume":"9","author":"Napoli","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.4389","article-title":"Functional precision cancer medicine\u2014moving beyond pure genomics","volume":"23","author":"Letai","year":"2017","journal-title":"Nat Med"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"672","DOI":"10.4236\/jct.2014.57076","article-title":"Cancer chemosensitivity testing: review","volume":"5","author":"Su","year":"2014","journal-title":"J Cancer Ther"},{"key":"ref58","first-page":"615","article-title":"Clonogenic and nonclonogenic in vitro chemosensitivity assays","volume":"69","author":"Weisenthal","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1126\/science.1254721","article-title":"Patient-derived models of acquired resistance can identify effective drug combinations for cancer","volume":"346","author":"Crystal","year":"2014","journal-title":"Science"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nrc4015","article-title":"Precision medicine for cancer with next-generation functional diagnostics","volume":"15","author":"Friedman","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"9538","DOI":"10.7150\/thno.55954","article-title":"Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept","volume":"11","author":"du Morand Puch","year":"2021","journal-title":"Theranostics"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","article-title":"Patient-derived tumour xenografts as models for oncology drug development","volume":"9","author":"Tentler","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nrc.2016.140","article-title":"Interrogating open issues in cancer precision medicine with patient-derived xenografts","volume":"17","author":"Byrne","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/ng.3967","article-title":"Patient-derived xenografts undergo mouse-specific tumor evolution","volume":"49","author":"Ben-David","year":"2017","journal-title":"Nat Genet"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nbt.2989","article-title":"Microfluidic organs-on-chips","volume":"32","author":"Bhatia","year":"2014","journal-title":"Nat Biotechnol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41573-020-0079-3","article-title":"Organs-on-chips: into the next decade","volume":"20","author":"Low","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1039\/C6LC01554A","article-title":"Organ-on-a-chip devices advance to market","volume":"17","author":"Zhang","year":"2017","journal-title":"Lab Chip"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/cancers18030411","article-title":"Ex vivo treatment response prediction in multiple myeloma: assay formats, clinical correlation, and future directions","volume":"18","author":"Oliver","year":"2026","journal-title":"Cancer"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.3390\/cancers15143602","article-title":"Advancing cancer therapy predictions with patient-derived organoid models of metastatic breast cancer","volume":"15","author":"\u00d6nder","year":"2023","journal-title":"Cancer"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s11626-021-00563-9","article-title":"Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform","volume":"57","author":"Pan","year":"2021","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.4143\/crt.2022.1630","article-title":"Establishment of patient-derived organoids using ascitic or pleural fluid from cancer patients","volume":"55","author":"Choi","year":"2023","journal-title":"Cancer Res Treat"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"18124","DOI":"10.1038\/s41598-023-45297-8","article-title":"Systematic review: predictive value of organoids in colorectal cancer","volume":"13","author":"Sakshaug","year":"2023","journal-title":"Sci Rep"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.medj.2024.08.010","article-title":"Patient-derived organoids in precision cancer medicine","volume":"5","author":"Tong","year":"2024","journal-title":"Med"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"102226","DOI":"10.1016\/j.tranon.2024.102226","article-title":"Patient-derived tumor organoids: a preclinical platform for personalized cancer therapy","volume":"51","author":"Taurin","year":"2025","journal-title":"Transl Oncol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s43586-022-00174-y","article-title":"Organoids","volume":"2","author":"Zhao","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41698-021-00168-1","article-title":"Patient-derived organoids as a predictive biomarker for treatment response in cancer patients","volume":"5","author":"Wensink","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"100161","DOI":"10.1016\/j.xcrm.2020.100161","article-title":"An automated organoid platform with inter-organoid homogeneity and inter-patient heterogeneity","volume":"1","author":"Jiang","year":"2020","journal-title":"Cell Rep Med"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"32","DOI":"10.20517\/cdr.2025.34","article-title":"Modeling methods of different tumor organoids and their application in tumor drug resistance research","volume":"8","author":"Yang","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40364-022-00356-6","article-title":"Clinical translation of patient-derived tumour organoids-bottlenecks and strategies","volume":"10","author":"Foo","year":"2022","journal-title":"Biomark Res"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"lnae016","DOI":"10.1093\/lifemedi\/lnae016","article-title":"Bridging the organoid translational gap: integrating standardization and micropatterning for drug screening in clinical and pharmaceutical medicine","volume":"3","author":"Yang","year":"2024","journal-title":"Life Med"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.7150\/thno.96027","article-title":"Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development","volume":"14","author":"Xiang","year":"2024","journal-title":"Theranostics"},{"key":"ref83","volume-title":"Establishes Nation\u2019s First Dedicated Organoid Development Center to Reduce Reliance on Animal Modeling","year":"2025"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"e2500501","DOI":"10.1200\/PO-25-00501","article-title":"Functional precision medicine using MicroOrganoSpheres for treatment response prediction in advanced colorectal cancer","volume":"10","author":"Gobits","year":"2026","journal-title":"JCO Precis Oncol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","article-title":"ctDNA-based molecular residual disease and survival in resectable colorectal cancer","volume":"30","author":"Nakamura","year":"2024","journal-title":"Nat Med"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II Colon Cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.isurg.2025.01.001","article-title":"Advantages and prospects of robotic surgery for colorectal cancer","volume":"8","author":"Fan","year":"2025","journal-title":"Int Surg"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"109397","DOI":"10.1016\/j.surg.2025.109397","article-title":"Guidelines for perioperative care in elective colorectal surgery: enhanced recovery after surgery (ERAS) society recommendations 2025","volume":"184","author":"Gustafsson","year":"2025","journal-title":"Surgery"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"e221100","DOI":"10.1001\/jamanetworkopen.2022.1100","article-title":"Colorectal cancer surveillance with circulating tumor DNA assay","volume":"5","author":"Venook","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by Ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1056\/NEJMra2301292","article-title":"Frailty in older adults","volume":"391","author":"Kim","year":"2024","journal-title":"N Engl J Med"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(24)00600-4","article-title":"Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data","volume":"26","author":"Sung","year":"2025","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1810895\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:21:27Z","timestamp":1775712087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1810895\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":92,"alternative-id":["10.3389\/fmed.2026.1810895"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1810895","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"article-number":"1810895"}}